American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, has promoted Barry H. Wells, M.D. as head of business development. Dr. Wells joined the company’s investor relations team in 2019.
In response to the COVID-19 pandemic, AGT™ CEO Jeff Galvin decided to turn “lemons into lemonade” by creating a COVID-19 testing lab. This new testing lab provided security for the in-person staff running experiments in the company’s research lab while also generating more than $10M in funding for its HIV cure program.
American Gene Technologies recently named Dr. Jeff Boyle as its new Chief Science Officer. Boyle was previously President at Ellume USA where he led the build out of the company’s 180,000 square foot manufacturing facility in Frederick, Maryland that produces the first COVID-19 home self-test to receive an EUA from the FDA.
American Gene Technologies, a clinical-stage biotechnology company, has reached a turning point in its HIV cure clinical trial: it began withdrawing participants from their antiretroviral drugs earlier this month. This clinical protocol, technically known as analytic treatment interruption (ATI), may ultimately determine if this gene therapy treatment can cure HIV.
American Gene Technologies CEO Jeff Galvin sits down with Michael Richman, President & CEO of NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. With four clinical readouts and another IND application for a fourth program expected this year, NextCure is proving to be an emerging leader in immuno-oncology.
After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.
American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue the developments in monogenic disease and immuno-oncology.
Today, a host of life sciences companies are utilizing gene therapy as a tool to find a cure for HIV. When discussing an HIV cure, there are two different possible targets: a “functional cure” where HIV is not eradicated but rather totally controlled without further ART treatment and a “sterilizing cure” that eliminates HIV completely from the body.
Montgomery County is well known for many transformative firsts in life sciences. First to sequence the human genome; first gene therapy for sickle cell, first cell therapy for COVID-19 — and that’s just the start.* Montgomery County is an epicenter for translating knowledge into life-changing treatment and cures, with gene and cell therapies representing some of the most promising advancements in human health.
“The Cure Chronicles” features thoughtful and compelling conversations with people in the HIV community. The video series launched in late March 2022 and can be found on AGT’s website and YouTube as well as other digital media platforms.
